From the Wires
Absorption Pharmaceuticals Names Laurence A. Levine, MD As The Company's Chief Medical Officer
Highly Acclaimed MD Joins Company's Leadership Team
By: PR Newswire
Jan. 8, 2013 06:06 AM
HUNTINGTON BEACH, Calif., Jan. 8, 2013 /PRNewswire/ -- Absorption Pharmaceuticals, makers of the world's first FDA-Approved topical treatment for premature ejaculation, Promescent, announced today that Laurence A. Levine, MD will assume the role of Chief Medical Officer (CMO). Dr. Levine will oversee the company's growth and education efforts, with a focus on getting Promescent written into protocols as a top-line treatment for premature ejaculation nationwide.
"We're thrilled to have such a highly respected and knowledgeable physician join our team," says Jeff Abraham, CEO of Absorption Pharmaceuticals. "We have been growing rapidly due to Promescent's proven effectiveness and securing Dr. Levine– whom has already provided invaluable assistance in reaching key opinion leaders in sexual medicine– adds to the credibility of this revolutionary product in the sexual medicine category. We look forward to the ongoing adoption of Promescent as the primary medical solution for premature ejaculation."
Dr. Levine received his medical degree from the University of Colorado Medical School, followed by a residency in general surgery at Tufts-New England Medical Center and in urology at the Harvard Program in Urology at Brigham and Women's Hospital in Boston. He has made a substantial contribution to the medical press in the form of peer-reviewed articles, books, book chapters, and Internet publications regarding male sexual dysfunction, fertility, chronic orchialgia and reconstructive urology. Currently, Dr. Levine is a professor of urology at the Rush University Medical Center in Chicago, and is in private practice with Uropartners, LLC. He has received multiple awards and honors; and served as a past-president of the Sexual Medicine Society of North America and the Chicago Urological Society.
"I am very excited to join Absorption Pharmaceuticals as Chief Medical Officer," says Dr. Levine. "Promescent is a ground-breaking, unrivaled product and doctors across the country are delighted to have a solution to a problem that previously has not received the attention it deserves. As an early adopter of the product as treatment for my patients with PE, I'm proud to lead the charge in spreading awareness of Promescent to the medical community."
Created by a urologist, Promescent is a lidocaine-based spray for premature ejaculation designed to absorb below the surface of the skin where nerve endings that control ejaculation are located, ultimately prolonging the time period of intercourse.
Promescent is available through doctors' offices, pharmacies and online at www.promescent.com.
For more information on Dr. Levine, go to www.urologyspecialists.net/meetus.html.
About Absorption Pharmaceuticals:
Absorption Pharmaceuticals is the maker of Promescent, the world's first FDA-approved topical treatment for premature ejaculation. Based in Huntington Beach, California, the company was founded in 2011 and has seen tremendous growth including distribution in doctors' offices, pharmacies, and online at www.promescent.com.
For more information contact:
SOURCE Absorption Pharmaceuticals
Latest AJAXWorld RIA Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week